Bridgewater Associates LP lowered its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 3.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 115,297 shares of the company’s stock after selling 4,529 shares during the period. Bridgewater Associates LP’s holdings in Bausch Health Companies were worth $3,387,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the stock. BDO Wealth Advisors LLC purchased a new position in Bausch Health Companies during the 1st quarter valued at approximately $36,000. Heritage Wealth Advisors purchased a new position in Bausch Health Companies during the 2nd quarter valued at approximately $42,000. Tarbox Family Office Inc. purchased a new position in Bausch Health Companies during the 2nd quarter valued at approximately $59,000. Ameritas Investment Company LLC purchased a new position in Bausch Health Companies during the 1st quarter valued at approximately $67,000. Finally, Odey Asset Management Group Ltd purchased a new position in Bausch Health Companies during the 1st quarter valued at approximately $86,000. Hedge funds and other institutional investors own 70.31% of the company’s stock.
In other news, Director Schutter Richard U. De bought 10,000 shares of the firm’s stock in a transaction on Wednesday, August 4th. The stock was acquired at an average cost of $25.01 per share, with a total value of $250,100.00. Following the transaction, the director now directly owns 317,109 shares in the company, valued at approximately $7,930,896.09. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 13.75% of the company’s stock.
Shares of BHC stock opened at $27.89 on Thursday. Bausch Health Companies Inc. has a 52-week low of $16.08 and a 52-week high of $34.80. The company has a debt-to-equity ratio of 39.55, a quick ratio of 0.79 and a current ratio of 0.99. The firm has a market capitalization of $10.00 billion, a P/E ratio of -7.75, a P/E/G ratio of 0.55 and a beta of 1.71. The stock has a 50 day moving average price of $28.14 and a 200 day moving average price of $29.31.
Bausch Health Companies (NYSE:BHC) last issued its earnings results on Monday, August 2nd. The company reported $0.97 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.95 by $0.02. The business had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.12 billion. Bausch Health Companies had a positive return on equity of 1,271.62% and a negative net margin of 15.18%. As a group, sell-side analysts forecast that Bausch Health Companies Inc. will post 4.24 EPS for the current year.
Bausch Health Companies Profile
Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
Further Reading: Technical Analysis of Stocks, How Can It Help
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHC).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.